Mgic signals operating expenses slightly below $190M-$200M range while extending quota share reinsurance to 2029

Nexstar targets leverage closer to 3x while expecting CW’s first profitable quarter in Q4 2026

Haemonetics outlines FY 2027 organic growth of 6%-9% while scaling CSL Persona PLUS rollout through calendar 2027

ATN expects 2026 adjusted EBITDA at high end or modestly above $183M-$193M range as tower sale proceeds continue

Global Payments signals $650M Worldpay run-rate expense synergies by end of 2028 while reiterating $2B+ 2026 shareholder returns